Compare DexCom, Inc. (DXCM) vs Five Below Inc (FIVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Five Below Inc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Five Below Inc trades at $211.87 (market cap $11.55B). The key difference: DexCom, Inc. is far larger — about 2.8× Five Below Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Five Below Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Five Below Inc for 46 Days on average.
| DXCM | FIVE | |
|---|---|---|
Market Cap | $31.86B | $11.55B |
Volume | 3,607,070 | 1,120,554 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $262.72 |
52-Week Low | $54.84 | $138.49 |
Typical Hold Time | 62 Days | 46 Days |
Enterprise Value | $31.32B | $12.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Five Below (FIVE) trades at $204.24, down 2.71% today, with strong analyst support (60% buy ratings) and a consensus price target of $298.44. The stock shows robust fundamentals with revenue growth from $3.6B in 2024 to $3.9B in 2025 and projected $5.3B in 2026, alongside consistent earnings beats. Technical indicators are mixed with a bearish overall signal but bullish oscillators, while recent news highlights digital marketing initiatives and board appointments.
FIVE presents a compelling growth story with raised 2026 guidance and strong profitability metrics (ROE 28.25%), though premium valuation (P/E 18.81) and execution risks amid consumer spending pressures warrant caution. Upside potential exists if traffic and margin trends sustain, but investors should monitor inflation impacts on discretionary retail spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
